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Malaria is one of the most devastating infectious diseases causing 1-3 million fatalities a 
year.  The majority of these cases occur amongst children in developing countries.  Malarial 
strains in these areas are exhibiting increasing resistance to canonical treatments proving the 
importance of new drug targets for anti-malarials.  Identification of new drug targets is 
dependent upon a better understanding of the molecular biology of the parasitic agent of malaria, 
Plasmodium.  The regulation of Plasmodium’s complex life cycle is still not well understood. 
Elucidation of signaling pathways involved in Plasmodium cell cycle regulation will provide 
insights into how the parasite thrives in human cells.  A subset of kinases, referred to as cyclin-
dependent kinases (CDKs), are crucial regulators of eukaryotic cell cycle progression.  In silico 
studies show high homology between mammalian CDK’s and a group of CDK-like Plasmodium 
kinases including PfPK5 (Plasmodium falciparum protein kinase 5).  Plasmodium homologues to 
CDK regulators, cyclins, have also been identified.  Understanding the role of PfPK5 in cell 
cycle regulation would require analysis of subcellular localization and cell cycle-dependent 
expression.  Immunofluorescence assays demonstrate that PfPK5 is localized in the nucleus.  
PfPK5’s expression profile, as determined by western blotting, shows highest expression in the 
schizont stage, the stage when the atypical multiple nucleated form of the parasite is observed.  
Possible PfPK5 interacting partners were detected by performing an anti-PfPK5 
immunoprecipitation assay.  Additionally, a hemagglutinin (HA)-tagged PfPK5 construct was 




interacting partners.  The characterization of PfPK5 and its interacting partners may prove useful 





 I would like to thank Dr. Debopam Chakrabarti for allowing me to work in his lab and for 
his guidance on this exciting project.  The independent research he has granted me greatly 
improved my knowledge in the field of molecular biology and prepared me for future research as 
a graduate student for which I am very grateful.  I would also like to thank Brittany Pease and 
Jennifer Mauser for all their wonderful help and support.   Without them and the rest of the 















Table of Contents 
Introduction ................................................................................................................................................................. vii 
The Parasitic Agent of Malaria ..........................................................................................................................2 
The Non-Canonical Life Cycle of Plasmodium ............................................................................................3 
Cell Cycle Regulation ..............................................................................................................................................6 
Plasmodium falciparum Protein Kinase 5 ...................................................................................................7 
Characterization of PfPK5....................................................................................................................................9 
Methods .......................................................................................................................................................................... 11 
Culturing Plasmodium falciparum................................................................................................................. 11 
Synchronization of Malarial Culture ............................................................................................................ 11 
Immunofluorescence Assays ........................................................................................................................... 11 
Preparation of Cover Slips ................................................................................................................................ 12 
Western Blots ......................................................................................................................................................... 13 
PfPK5-HA Expression ......................................................................................................................................... 13 
Anti-PfPK5 Immunoprecipitation ................................................................................................................. 14 
PfPK5-HA Cloning ................................................................................................................................................. 15 
Plasmodium Transfection.................................................................................................................................. 16 




PCR Screen of PfPK5-HA Transfection ....................................................................................................... 17 
Southern Blot of PfPK5-HA Transfection .................................................................................................. 17 
Results ............................................................................................................................................................................. 19 
PfPK5 Demonstrates Nuclear Localization and Co-localization with PfCyclins ..................... 19 
Expression Profile of PfPK5 and PfCyclin3 Indicate Peak Expression during Late Schizont 
Stages .......................................................................................................................................................................... 23 
Anti-PfPK5 Immunoprecipitation Two Possible PfPK5 Interacting Partners ......................... 25 
Generation of PfPK5-HA Construct .............................................................................................................. 26 
PfPK5-HA Transfection Shows Expression of the HA ......................................................................... 29 
PCR Screening Demonstrates PfPK5-HA Was Not Integrated into the Parasite CG6 Locus
........................................................................................................................................................................................ 31 
PfPK5-HA Does Not Co-localize with Endogenous PfPK5 ................................................................. 32 
Discussion ...................................................................................................................................................................... 33 
Significance of Work ............................................................................................................................................ 36 





Table of Figures 
Figure 1 -  Plasmodium life cycle .............................................................................................................................5 
Figure 2 – IFA: PfPK5 vs Histone ............................................................................................. 20 
Figure 3 – IFA: PfPK5 vs PfCyc1 ............................................................................................. 21 
Figure 4 – IFA: PfPK5 vs PfCyc2 ......................................................................................................................... 22 
Figure 5 – IFA: PfPK5 vs PfCyc 3........................................................................................................................ 23 
Figure 6 - Stage-specific anti-PfPK5 Western Blot........................................................................................ 24 
Figure 7 - Stage-specific anti-PfCyc3 Western Blot ...................................................................................... 24 
Figure 8 – Densitometry of PfPK5 Western (8A) and PfCyc3 Western (8B). ..................................... 25 
Figure 9 – Silver Stained SDS Gel of PfPK5 Immunoprecipitation ........................................................ 26 
Figure 10 - Agarose Gel of PfPK5-HA PCR Product. .................................................................................. 27 
Figure 11 – Screening of  PfPK5-HA-pGEMT Clones ................................................................................. 27 
Figure 12 – Agarose Gel of Digested PfPK5-HA-pGEMT ......................................................................... 28 
Figure 13 – Agarose Gel of Digested pDC2-1600-GFP-MAHRP ............................................................ 28 
Figure 14 - Screening of PfPK5-HA-pDC2-1600 Clones............................................................................. 28 
Figure 15 - Anti-PfPK5 Western Blot ................................................................................................................. 30 
Figure 16 - Anti-HA Western Blot........................................................................................................................ 31 
Figure 17- PCR Screening of PfPK5-HA Integration.................................................................................... 32 





In 2008 alone the Center for Disease Control reported up to 311 million cases of malaria 
worldwide. 1,003,000 of these cases resulted in death, most of the fatalities being amongst young 
children in developing countries.  90 countries are considered malarious putting 36% of the total 
world population at risk with almost half of the countries being located in sub-Saharan Africa 
(19).  The disease is contracted from mosquitoes and as such resistance to pesticides like DDT in 
malaria-endemic countries (10) has greatly hindered alleviation of the disease.  This threat is 
being intensified by the fact that Plasmodium strains have been developing drug resistance to 
canonical anti-malarials.  Thus the need for new anti-malarials is of vital importance (4). 
Malaria: A Devastating Tropical Disease 
Malaria has been considered one of the most important tropical diseases (19).    Currently 
there is no effective vaccine (13).  The threat of malaria continues to grow as traditional 
treatments are becoming obsolete with the emergence of drug resistant parasites.  Drug resistance 
has occurred rapidly over the past few decades.  Quinine is a natural antimalarial that has been 
used since the 1600s (23) but is rare and thus expensive making it far from an optimal treatment 
for underdeveloped countries.  A synthetic equivalent, chloroquine, was created to circumvent 
this problem in the mid 1940s (23).  Although drug resistance to quinine was not observed until 
1910 (23) chloroquine resistance emerged as early as 1957 (23).  Sulfadoxine-pyrimethamine 
drugs were introduced as a way to treat malaria in 1967 but resistance was reported in that same 




is one of the only affordable drug treatments in Africa (23).  Another common treatment, 
mefloquine, was introduced in the late 70s and after only 5 years mefloquine resistance was 
reported (23).  Inadequate drug supplies, improper dosing regimens and the high price of more 
effective anti-malarials continue to aggravate the problem of drug resistance in developing 
countries (3). From 1925 to 1996 1,223 new drugs were designed and of these only 3 were anti-
malarials (10).  As such malaria has resurfaced in countries where it had been previously 
eradicated such as Iraq and Turkey (19). 
Initial symptoms of malaria are flu-like including high fever, headache and muscle pain.  
High fever associated with malaria subsides and reoccurs about every 48 hours.  Other 
complications linked to malaria are renal failure, pulmonary edema, cardiovascular impairment 
and anemia (22).  
The Parasitic Agent of Malaria 
The causative agent of malaria is the protozoan parasite Plasmodium.  The Plasmodium 
species are apicomplexans.  Common to the apicomplexan phylum are apical organelles that 
reside in the anterior end of the organism’s invasive form (16).  These proteins form an apical 
complex which is involved in the invasion of host cells (16).  There are four parasitic species that 
cause malaria in humans: Plasmodium vivax, Plasmodium ovale, Plasmodium malariae and 
Plasmodium falciparum with P. falciparum and P. vivax being the more widely distributed and 
encountered species.  P. falciparum, the most lethal of the species, is responsible for 
approximately 95% of malaria related deaths (11).  Virulence factors that contribute to the 




endothelial cells causing agglutination of non-infected red blood cells in blood vessels thus 
disrupting blood flow (rosetting) (17).  In vitro tests have demonstrated that TNFα, a pro-
inflamatory cytokine, may have a role in the pathogenicity of P. falciparum.  In vitro studies 
have also shown that TNFα has the ability to modulate ICAM-1, an endothelial cell involved in 
rosetting (17).  Patients infected with malaria exhibit raised TNFα concentrations (17).  
Antigenic variation is a common evasion mechanism and has been demonstrated in P. 
falciparum (2).  Studies report that the antigenic variation of P. falciparum erythrocyte 
membrane protein 1 (mbp1) resulted in different expression patterns on the surfaces of infected 
red blood cells (2).  Exponential increase in parasitemia from schizont to merozoite and the 
transitory extracellular exposure of merozoites are likely to aid in evasion from host immune 
cells in most Plasmodium species. 
The Non-Canonical Life Cycle of Plasmodium 
The Plasmodium life cycle is atypical and complex.  It has adapted to survive in 
vertebrate and invertebrate hosts (16).  In mosquitoes Plasmodium demonstrates a sexual life 
cycle in the midgut of the Anopheles female vector.  However, upon invasion of the host it 
arrests cell cycle until it has successfully penetrated host hepatocyctes where the parasite 
undergoes asexual replication, egression of hepatocytes and invasion of new red blood cells 
(RBCs) (14).   
On average 15 parasitic sporozoites are transferred from mosquito saliva to a human host 
(18). Upon entry into the blood stream they travel to the liver and invade hepatocytes where they 




invade erythrocytes. Once inside the erythrocyte the parasite enters a unique asexual, intra-
erythrocytic life cycle. The first phase of the asexual life cycle is referred to as the ring stage.  
Ring stage parasites take up a minimal volume of the red blood cell.  They feed on hemoglobin 
and increase in size until they reach the trophozoite stage.  Transition from ring to trophozoite is 
also marked by the development of a purple pigmentation, the result of hemozoin crystal 
formation from the toxic heme byproduct of hemoglobin metabolism.  The trophpozoite stage is 
followed by the schizont stage, which occupies almost the entire RBC.  Most DNA replication 
occurs during this stage.  Multiple rounds of DNA replication without cytokinesis result in a 
multinucleated schizont.  The RBC eventually lyses releasing a variable number of segmenters 
(7).  Segmenters that do not quickly re-infect new RBCs die or arrest their cycle for 
differentiation into gametocytes.  Gametocytes represent a reproductive sexual stage.  After 
ingestion by the female mosquito (male feed on plant nectar) gametocytes undergo 
gametogenesis in the mid-gut of the insect.  Gametogenesis involves the fusion of 2 gametocytes 
to a zygote, which differentiates into an ookinete.  The ookinete crosses the peritrohpic 
membrane and midgut epithelium to become immobilized at the epithelium basal lamina where it 
develops into an oocyst (14).  From the oocyst thousands of sporozoites are formed (14) which 
travel to the salivary glands to await re-infection.  This complex life cycle can be visualized in 





Figure 1 -  Plasmodium life cycle. www.nature.com/.../fig_tab/nature07361_F1.html 
Erythrocytic-shizogony has no clear correlation to the traditional cell cycle progression 
demonstrated by eukaryotes (7).  Traditionally cells progress through four cell cycle phases: G1, 
S, G2, and M. Gap phases (G1 and G2) serve as check points for progression into DNA synthesis 
(S) and mitosis/meiosis (M).  Entry into the S phase from G1 checks that all DNA has been 
replicated, that damaged DNA has been repaired, and that environmental conditions favor 
synthesis (20).  Once the synthesis has been initiated it will go to completion (20).  Entry into M 
from G2 checks that replication has been completed, damaged DNA has been repaired and that 
the cell is large enough to accommodate cell division. A mitotic checkpoint ensures sister 
chromatids attach to spindles on opposite polar ends.  If checkpoint requirements are not met the 
cell cycle is arrested to ensure fidelity of genetic transfer (20).  Interestingly, during the 
trophozoite and schizont stages Plasmodium exhibits multiple rounds of synthesis and mitosis 
without gap phases. 
Although the intra-erythrocytic asexual life cycle of P. falciparum has no clear 




regulators, cyclin dependent kinases (CDKs), have been identified as well as their regulating 
subunits, cyclins (6).  This evidence suggests that though the cell cycle progression diverges in 
Plasmodium, they may undergo similar regulating mechanisms observed in traditional 
eukaryotes such as regulation by CDKs and cyclins.  Understanding these mechanisms would 
help elucidate the signaling pathways involved in Plasmodium 
Cell Cycle Regulation 
Signaling pathways are regulated and propagated by various protein kinases and 
phosphatases.  There are seven clusters of protein kinases associated with eukaryotes: 1. CK1 
(casein kinases) 2. CMGC (cyclin dependent kinases), MAPK (mitogen activated protein 
kinase), GSK3 (glycogen synthase kinase), CLKs (CDK-like) 3. TKL (tyrosine kinase-like) 4. 
AGC (PKA, PKG and PKC kinases) 5. CAMK (calcium/calmodulin dependent kinases) 6. STE 
(MAPK regulators) 7. TyrK (tyrosine kinases) (5).  The Plasmodium kinome however lacks 
TyrK and STE families.  In fact it has been determined that the P. falciparum genome contains 
only 65 protein kinases (21), in comparison to the human genome which encodes 500 protein 
kinase genes. 
Cell cycle signaling pathways in eukaryotes are regulated by CDKs.  The regulating unit 
of CDKs, referred to as cyclins, determine CDK activity.  CDKs exhibit steady state expression 
while cyclins are degraded and synthesized in a cyclical manner.  In typical eukaryotes CDK 
activity is low during the G1 phase due to inhibition of cyclin synthesis and high levels of cyclin 
degradation (20).  During the transition from G1 to S, cyclin synthesis is induced and cyclin 




during S, G2 and M phases (20).  Following the completion of mitosis, Cdc20 (cell division 
cycle protein 20) and Cdh1 (APC activating protein) (members of the anaphase-promoting 
complex APC) label cyclins for degradation which reduces CDK activity and brings the cell 
cycle back to the G1 phase (20).  CDKs show preference for cyclin binding partners (6).  Thus 
the appropriate CDK can be activated in its respective cell cycle phase.  Generally CDKs also 
require ATP binding and activation by cyclin activating kinases (CAKs) in addition to cyclin 
binding (5). 
PfCDKs exhibit 40-60% homology with eukaryotic kinase domains of CDKs (6) 
suggesting similar functions.  There are however large extensions or insertions in these 
conserved sequences, which may be indicative of unique regulatory features.   
Plasmodium falciparum Protein Kinase 5 
PfPK5 is a proline-directed Ser/Thr CDK-like kinase that was isolated using sequences of 
mammalian CDK2 and CDK1 (14).  PfPK5 has been shown to have several sequence 
characteristics and functionalities that suggest similar roles and regulation to CDKs.  PfPK5 is 
the closest homologue to metazoan CDKs demonstrating roughly 58% identity with CDK2 (11).  
PfPK5 shows strong structural similarities with CDK2 especially in the cyclin binding domain.  
CDK2 contains a PSTAIRE sequence involved in cyclin binding and in silico studies show that 
PfPK5 has a conserved PSTAIRE-like sequence (PSTTIRE) (6).  Homology between amino acid 
sequences in the catalytic ATP binding domain in eukaryotic CDKs and PfPK5 has also been 
identified (11).  PfPK5 also demonstrates 60% sequence homology with CDK1 and CDK5 (6) 




In addition to sequence similarity, PfPK5 shows similar activation and inhibition activity 
with CDKs.   Activation of CDKs requires phosphorylation of a conserved threonine residue.  In 
mammals this residue is Thr-169 (7).  The analogous residue of the Thr-169 residue in PfPK5 is 
Thr-158 (9).  It was demonstrated that mutagenesis of Thr-158 to glutamic acid (mimics 
phosphorylated Thr) enhanced PfPK5 activity while replacement with valine (cannot be 
phosphorylated) prevented PfPK5 from exhibiting activity.  PfPK5 was also shown to respond to 
CDK 2 inhibitors (11). 
While PfPK5 shares several characteristics with its CDK homologues, it also 
demonstrates many unique characteristics.  PfPK5 shows promiscuity in cyclin binding partners 
and has also been shown to be activated by non-cyclin vertebrate activators such as RINGO from 
Xenopus (12).  Activation by proteins such as RINGO, which share no sequence homology to 
cyclins, suggests that the P. falciparum genome may code for cryptic cell cycle regulators which 
cannot be identified based solely on database searches (14).  Not only does PfPK5 have a 
promiscuous nature but it demonstrates low-level phosphorylation in the absence of cyclins, 
though cyclins significantly enhance activity (12).  Therefore cyclins may not have as great a 
role in the regulation of PfPK5.  Determination of regulatory mechanisms involved in the PfPK5 
signaling pathway has therefore provoked much interest.  The differences observed in CDKs and 
PfPK5 suggest that proteins unique to the parasite associate with and regulate PfPK5.  If 




Characterization of PfPK5 
The expression profile of Cdc2, a yeast CDK homologue of PfPK5, and its cyclin-like 
regulator, Cdc13, show similar cyclical expression both demonstrating peak expression in the M 
phase of the cell cycle (8).  These are the expected results for a CDK and its cyclin subunit; 
expression of the cyclin will oscillate in accordance with cell cycle progression and because 
CDK activity is dependent upon cyclin binding, CDK expression should mirror cyclin 
expression.  To determine if PfPK5 exhibits this type of expression profile, stage-specific 
western blots were performed against PfPK5 and PfCyc3.  The data gathered from this 
experiment will determine if PfPK5 and PfCyc3 are possible interacting partners.  This will also 
indicate which stage exhibits the highest PfPK5 expression, suggesting when the kinase is active 
and proposing the cell cycle phase PfPK5 is involved in regulating. 
Immunofluorescence assays were also conducted to determine if PfPK5 demonstrates 
nuclear localization as would be required if PfPK5 is involved in cell cycle regulation.  The 
assays will also be used to determine if PfPK5 co-localizes with PfCyclins1-3.  Proteins involved 
in the same pathway often exhibit co-localization, which aids in substrate channeling and 
efficiency.  Co-localization would support PfPK5 interaction with PfCyclins. 
Identification of the entire complement of positive and negative PfPK5 regulators and 
each of their functions is necessary in order to understand the Plasmodium life cycle (6).  To 




 An HA-tagged (hemagglutinin) PfPK5 construct was created for Plasmodium 
transfection for use in further characterization.  An HA-tag immunoprecipitation will validate the 
data generated by the PfPK5 immunoprecipitation.  
 Here we have further characterized PfPK5’s role in cell cycle regulation through 
immunofluorescence assays and determination of its expression profile. Furthermore, we have 
identified potential interacting partners of PfPK5 by performing an immunoprecipitation. The 
generation of a PfPK5-HA construct will also prove useful in future work aimed at uncovering 
the role PfPK5 plays in cell cycle regulation, as well as identifying previously unidentified 







Culturing Plasmodium falciparum 
 Cultures were maintained in RPMI 1640 media supplemented with 5% albumax at a 4% 
hematocrit in a 5% CO2 humidified incubator at 37°C.  Fresh media was added daily.  Cultures 
were split as needed to maintain 3-5% parasitemia (as determined my geimsa staining and 
microscopy).  For use in experiments, cultures were brought up to 10-20% parasitemia before 
being harvested (see below for harvesting protocol).  
Synchronization of Malarial Culture 
 Cultures were resuspended and centrifuged at 2000rpm, room temperature, for 5min.  
The pellet was resuspended in 5X the pellet volume of 5% sorbitol.  The culture was incubated 
with sorbitol for 15min at 37°C.  The culture was centrifuged as before and the pellet was 
washed twice in 25mL RPMI 1640.  The pellet was resuspended in its original volume of culture 
and plated back in a non-treated 100cm by 20cm culture dish.  
Immunofluorescence Assays 
 Asynchronous malarial culture (P. falciparum 3D7) was resuspended and centrifuged at 
1500rpm, 4°C for 3min (2ml/IFA).  The pellet was resuspended in PBS (1ml/1ml culture) and 
centrifuged at the same conditions as before.  The pellet was resuspended in fixing solution (4% 
glutaraldehyde, .0075% paraformaldehyde) and incubated at 37°C for 30min.  After incubation 




made permeable by treatment with 0.1% triton-X100 (1ml/1ml culture) for 10min at room 
temperature.  Cells were centrifuged as before.  The pellet was resuspended in 125mM glycine 
and incubated for 10min at room temperature to reduce remaining aldehydes.  Then the cells 
were centrifuged again as before.   
 The pellet was then resuspended in 3% BSA for blocking at room temperature for 1 hour.  
Cells were centrifuged as before and resuspended in PBS. 1ml per IFA was aliquoted into a 
microcentrifuge tube.  Primary antibodies were added and incubated at 4°C overnight with the 
following dilutions: rabbit αPfPK5 1:2000, chicken αPfCyc1-3 1:5000, goat αPfPK5 1:1000.  
Cells were centrifuged at 2000rpm, 4°C for 2 min.  The pellet was rinsed 3 times in PBS for 
5min and centrifuged as before following each wash.  Secondary antibody was added and 
incubated for two hours at room temperature with the following dilutions: αrabbit-
AlexaFlur™555 1:1000, αchicken-AlexaFlur™488 1:1000, αgoat-AlexaFlur™488 1:1000.  
Cells were centrifuged as before.  Again the pellet was washed 3 times with PBS as before.  
Cells were centrifuged as before and 4μl were added to prepared cover slips (see below) and 
incubated for 30min at room temperature.  Fixed cover slips were mounted on a microscope slide 
over 2μl of mounting solution. 
Preparation of Cover Slips 
 Cover slips were rinsed in 70% ethanol followed by a PBS rinse. 200μl of poly-L lysine 
were added to the cover slip and incubated for 30min.  The poly-L lysine was then removed and 







 P.falciparum 3D7 culture was resuspended and treated with 0.05% saponin.  Cells were 
centrifuged at 4000rmp, 4°C for 10min.  The pellet was rinsed twice in PBS and centrifuged as 
before. Parasite lysate was obtained from the pellet by treatment with 8M urea.  Cell cultures 
were harvested every 8 hours for 48 hours.  100μg of each time point was run on an SDS-PAGE 
gel and transferred to a PVDF membrane by semi-dry transfer at 15V for 45min.  The membrane 
was blocked in 5% milk-PBS-t for 45 min.  Primary antibody was added and incubated overnight 
at 4°C with the following dilutions: rabbit αPfPK5 1:5000, chicken αPfcyc3- 1:2500.  The 
membrane was washed in 5% milk-PBS-t 3 times for 10min.  Secondary antibody was then 
added and incubated at room temperature for 2 hours at the following dilutions: αrabbit-HRP 
1:10000, αchicken-HRP 1:10000.  Following incubation the membrane was washed 3 times in 
PBS-t and once in PBS.  Finally, the membrane was developed by chemiluminescence using the 
Immun-Star Western Kit from Biorad. 
PfPK5-HA Expression 
 PfPK5-HA and P. falciparum 3D7 parasite pellets were obtained as above.  Parasite 
lysate was obtained by treatment with M-per cell lysis buffer (1μl lysis buffer/1mg pellet 
incubated on ice for 30min while vortexing every 5min, centrifuged down and the supernatant 
collected).  100ug of each lysate was run on an SDS-PAGE gel and transferred overnight at 10V.  




dilutions were as follows: goat αHA 1:1000, rabbit αPfPK5 1:1000.  Secondary antibody 
dilutions were as follows: donkey αgoat-HRP 1:2000, αrabbit-HRP 1:2000.   
Anti-PfPK5 Immunoprecipitation 
 20μl of control resin and 20μl of A/G plus resin were added to separate spin columns and 
centrifuged at 1000rpm, 4°C for 1min and the flow-through discarded.  Columns were washed 
with coupling buffer.  10μg of anti-PfPK5 antibodies were diluted with dH2O and coupling 
buffer and added to each column for a 1 hour incubation at room temperature.  Columns were 
centrifuged as before and washed twice with coupling buffer.   Columns were then incubated 
with coupling buffer, 2.5mM DSS and dH2O for 1 hour to crosslink antibody to beads.  The 
columns were washed twice with elution buffer and twice with immunoprecipitation lysis/wash 
buffer.  1mg of P. falciparum 3D7 lysate was added to the control beads and the anti-PfPK5 
crosslinked beads and incubated at 4°C overnight.  Columns were centrifuged as before and 
washed 3 times with immunoprecipitation lysis/wash buffer and once with conditioning buffer.  
The beads were then resuspended in gel loading buffer and prepared for SDS-PAGE analysis and 
silver staining. 
Silver Staining 
 The SDS gel was rinsed briefly with ultrapure water and fixed overnight in fixative 
solution (40% ethanol, 10% acetic acid).  Fixative solution was decanted and the gel was washed 
in 30% ethanol for 10min.  Ethanol was decanted and the gel was incubated for 10 min in 
sensitizing solution (0.02% sodium thiosulfate).  Sensitizing solution was decanted and the gel 




The gel was stained by a 15min incubation in staining solution (0.1% silver nitrate).  Stainer was 
decanted and the gel was rinsed for 30 sec in ultrapure water.  The gel was developed by 
incubation in the developer solution (2% sodium carbonate, 0.04% formalin) for ~25min (until 
bands of desired intensity are observed).  10ml of stopper solution (5% glacial acetic acid) was 
added to gel in developing solution and incubated 10min to stop developing.  Developer and 
stopper were decanted and gel was rinsed in ultrapure water for 10min.  
PfPK5-HA Cloning 
 PfPK5-HA, flanked by Xho1 and AvrII cut sites, was generated via reverse transcriptase 
PCR.  PCR settings were as follows: 42°C-30”; 95°C-30”; [95°C-30”; 46°C-30”; 68°C-6’]X5; 
[95°C-30”; 52°C-30”; 68°C-6’]X35; 68°C.  The PCR product was purified (Promega PCR 
Clean-Up System) and ligated into pGEMT easy vector (Promega pGEMT Easy Vector System) 
and transformed into E. coli XL10 Gold cells.  Accuracy of the nucleic acid sequence was 
confirmed by dideoxy sequencing.  PfPK5-HA-pGEMT was digested with Xho1 and AvrII 
overnight at 37°C.  The digest was heat inactivated at 80°C and run on an agarose gel. PfPK5-
HA (insert) was extracted from the gel.  pDC2-1600-MAHRP was digested in the same manner, 
treated with phosphatase for 20 min at 65°C, run on an agarose gel and the pDC2-1600 (vector 
backbone) was extracted.  The insert and vector were ligated with quick ligase and transformed 
into E. coli XL10 ultra-competent cells.  These clones were also sequenced confirmed by 





 2.5 mL of ring-stage P. falciparum integrase culture was resuspended and centrifuged at 
1500rpm, 25°C for 3min.  The pellet was resuspended and washed with cytomix (1ml/1ml 
culture) and centrifuged as before.  The pellet was resuspended in 300μl cytomix.  100ug of 
PfPK5-HA and 25ug of pINT in cytomix were added to the resuspended pellet.  The cells were 
iced for 30sec and electroporated.  The transfection was plated in a 6 well plate with 5ml RPMI 
1640 media and 280μl of blood.  After 4 hours the transfection was treated with drug media 
(RPMI 1640/G-418/Blasticidin/WR 99210). 
Genomic DNA Extraction of PfPK5-HA 
 Parasite pellet was obtained as described under Western Blot.  Genomic DNA extraction 
was performed on the pellet.  The pellet was first washed in 5mL cell wash buffer (50mM Tris 
pH7.5, 100mM NaCl), centrifuged and the supernatant discarded.  The pellet was resuspended in 
1mL cell wash buffer.  250mM EDTA, 250μl 10% SDS and 25μl RNase (10mg/mL) were added 
and incubated at 37°C for 1 hour.  250μl of 10mg/mL proteinase K was added and incubated at 
60°C for 2 hours.  After incubation, an equal volume of phenol-chloroform-isoamyl alcohol was 
added to the lysate and centrifuged at 7000g, 10 min, at room temperature.  The aqueous layer 
was removed and kept.  An equal volume of chloroform-isoamyl alcohol was added, incubated at 
room temperature for 5min and centrifuged as before.  The aqueous layer was again removed and 
kept.  The aqueous phase volume was diluted with 10mL TE buffer followed by addition of 1mL 




washed in 5mL 70% ethanol.  The ethanol was removed and the pellet air dried for 45min.  
200μl of TE buffer was added to the pellet and then stored overnight at 4°C.   
PCR Screen of PfPK5-HA Transfection 
 3 PCR reactions were set up with digested  PfPK5-HA genomic DNA (Nco1 at 37°C for 
4 hours) as template DNA and the following primers: 1) F:5’ of CG6 gene and R:3’BSD gene 2) 
F:5’ of PfPK5 gene and R:3’ of CG6 gene 3) F:5’ of CG6 gene and R: 3’CG6 gene.  PCR 
conditions were as follows: 95°C-2min’; [95°C-30”; 45°C-30”; 72°C-6min]X5; [95°C 30”; 
50°C-30”; 72°C-6min]X35; 72°C 10min.  PCR products were run on an agarose gel for 
visualization. 
Southern Blot of PfPK5-HA Transfection 
Generation of membrane 
 PfPK5-HA genomic DNA (same as used in the PCR Screen) and 3D7 genomic DNA 
(obtained as above) was digested at 37°C overnight with XmaI and EcoRV.  Undigested and 
digested samples were run on an agarose gel.  The gel was rinsed in denaturing solution for 
15min twice.  The gel was then rinsed briefly in water and then in neutralizing solution for 
45min.  A nitrocellulose membrane was wet with water and then 20X SSC.  Next the gel was 
transferred to the membrane overnight via capillary action.  Lanes on the membrane were 
marked with a soft lead pencil.  The membrane was then soaked in 5X SSC for 5min and placed 
on a wet paper towel for UV crosslinking to immobilize DNA.  The membrane was dried at 





 The membrane was placed in a hybridization bottle, DNA side up. 20mL of pre-
hybridization buffer (10% NaPPi, 10%SDS, 100XDenhalt’s Solution, 20XSSC) and 200μl of 
1mg/mL sonicated salmon sperm DNA were added to the membrane and incubated in the 
hybridization oven at 60°C for 2 hours.   
Radioactive label of probe 
 (Strategene Prime-it II kit): 25ng of template DNA (PfPK5 sequence being labeled), 10μl 
of random oligonucleotide primers and water were added up to 34μl in a microcentrifuge tube.  
The reaction was boiled for 5min and briefly centrifuged at room temperature.  10μl 5X dATP 
primer buffer, 5μl of labeled nucleotide ([α-
32
P]dATP at 3000Ci/mmol), and 1μl Exo(-) Klenow 
enzymes were added to the reaction tube and incubated at 37°C for 10min.  2μl of stop mix were 
added to reaction tube following the 10min incubation.   
Hybridization 
 The denatured probe was added to membrane/pre-hybridization solution and incubated 
overnight at 60°C in the hybridization oven.  The membrane was then washed in 50mL wash 
buffer (2X SSC, 10%SDS, 10%NaPPi and water) for 5min in the hybridization oven.  This 
solution was decanted and the wash was repeated.  The membrane was next washed in 60mL 
wash buffer 2 (0.2X SSC, 10%SDS, 10%NaPPi and water) for 15min in the hybridization oven.  
This solution was decanted and the wash repeated twice.  Bands on the membrane were finally 







PfPK5 Demonstrates Nuclear Localization and Co-localization with PfCyclins 
 A protein’s role in cellular biology dictate’s its subcellular localization.  Proteins 
involved in nuclear processes thus localize to the nucleus.  To determine if PfPK5 localizes to 
the nucleus, supporting its suggested role in cell cycle regulation, immunofluorescence assays 
(IFAs) have been performed.  IFAs use fluorophore-tagged antibodies and confocal microscopy 
to determine a protein’s localization.  Here anti-histone antibody was used as a nuclear marker.  
First, infected red blood cells are fixed with formaldehyde to preserve the parasite’s intra-
erythrocytic location as wells as endogenous localization of parasitic proteins.  The erythrocyte 
and parasite membranes were made permeable by treatment with triton-X100 so that antibodies 
would have access to parasitic proteins.  After incubation with primary antibodies (αPfPK5 and 
αhistone) the cells were washed and incubated with the appropriate fluorophore-tagged 
antibodies.  The cells were washed again and fixed to microscope slides for visualization via 





Figure 2 - PfPK5 vs histone IFA results show nuclear localization of PfPK5.  PfPK5 is visualized in green and 
histone in red.  Overlay images merge PfPK5 and histone images and superimpose them on DIC images of the 
cell.  Yellow spots indicate overlap of red (histone) and green (PfPK5).  DIC: differential interference contrast. 
 
 To determine if PfPk5 demonstrates co-localization with P. falciparum cyclins, thus 
indicating potential cyclin-mediated regulation of PfPK5, additional IFAs were performed using 
antibodies against identified PfCyclin homologues.  Results in figures 3-5 show that PfPK5 co-
localizes with PfCyclin1 (fig 3), PfCyclin2 (fig 4) and especially with PfCyclin3 (fig 5).  PfCyc1 
and PfCyc2 show partial recruitment to PfPK5 but both also localize in the cytoplasm where 
PfPK5 is absent.  PfCyc3 however shows tight co-localization throughout the intra-erythrocytic 
stages. 





Figure 3 - PfPK5 vs PfCyc1 IFA results show partial recruitment of PfCyc1 (green) by PfPK5 (red).  Merged 
images represent localization of both proteins with yellow representing overlap of green (PfCyclin1) and red 







Figure 4 - PfPK5 vs PfCyc2 IFA results show partial recruitment of PfCyc2 (green) by PfPK5 (red).  Merged 
images represent localization of both proteins with yellow representing overlap of green (PfCyclin1) and red 





Figure 5 - PfPK5 vs PfCyc 3 IFA results show recruitment of PfCyc3 (green) by PfPK5 (red) throughout the intra-
erythrocytic stages with top row representing early infection (late ring/early trophozoite) and the last row 
repreenting late infection (late trophozoite/early shizont).  Merged images represent localization of both proteins 
with yellow representing the overlap of green (PfCyclin3) and red (PfPK5).  Overlay images superimpose merged 
images on DIC images.  DIC: differential interference contrast. 
Expression Profile of PfPK5 and PfCyclin3 Indicate Peak Expression during Late Schizont 
Stages 
 To determine when PfPK5 is most actively expressed, stage-specific western blots were 
performed.  Stage-specific western blots were also generated against PfCyc3 since localization 
studies and previous data suggested possible interactions between PfPK5 and PfCyc3.  Culture 
was harvested every 8 hours throughout the parasite’s 48 hour life cycle.  The cell-free extracts 
were resolved by SDS-PAGE gel electrophoresis.  PfPK5 migrates through the gel as expected 




52kDa protein.  Results in figures 6-8 show cyclical expression of PfPK5 and PfCyc3.  Both also 
demonstrate a trend of increasing levels of expression from early infection to late infection.  
PfPK5 and PfCyc3 expression peaks in the late schizont stage.  Densitometry (fig 8A-8B) 
confirms the qualitative trend of increasing cyclical expression demonstrated by band intensity in 
the western blots. 
 
 
Figure 6 - Stage-specific anti-PfPK5 western blot.  The band at 33kDa is PfPK5.  Segmenter/Early Ring: re-
infecting parasites and up to 8 hours post infection.  Late ring: up to16 hours post infection.  Early trophozoite: up to 
24 post infection.  Late trophozoite: up to 32 hours post infection.  Early schizont: up to 40 hours post infection.  




Figure 7 - Stage-specific anti-PfCyc3 western blot demonstrates PfCyc3 expression profile.  The band at 52kD is 








8A                                                                         8B                                                                       
          
Figure 8 - Figure 8A and 8B. Densitometry of PfPK5 and PfCyclin3 stage-specific expression quantitatively 
show a trend of increasing expression from early infection to late infection.  PfPK5 and PfCyc3 expression peaks 
during the late schizont stage.  Stages are represented as in figures 6 and 7.    
        
Anti-PfPK5 Immunoprecipitation Two Possible PfPK5 Interacting Partners 
 In order to pull-down possible PfPK5 interacting partners, anti-PfPK5 antibodies were 
crosslinked to agarose beads through their interactions between Protein A/G which is 
immobilized on the resin.  Asynchronous lysate was incubated with the crosslinked resin 
overnight and the beads were washed, resuspended in gel loading buffer, centrifuged down and 
the supernatant run on an SDS-PAGE gel.  Control resin lacked the A/G protein and was thus not 
able to crosslink with antibodies.  Control resin was also incubated with asynchronous parasite 
lysate, washed and loaded on the gel.  The SDS gel was visualized by silver staining as can be 















































PfPK5 interacting partners.  Bands visualized at 50kDa and 25kDa may be attributed to the 
heavy and light chains of the antibodies.  Mass spectrometry will be used to identify these 
proteins and further characterization of the putative interacting partners will determine the type 
of interaction, if any, the proteins share with PfPK5. 
 
Figure 9 - Visualization of SDS gel after silver staining reveals possible PfPk5 interacting partners.  Control: 
Agarose beads lacking A/G protein conjugation. 
FT:  Flow-through after primary antibody incubation 
Red arrow: Bands at 150kDa, 100kDa, 70kDa and ~30kDa represent potential interacting partner of PfPK5 
 
Generation of PfPK5-HA Construct 
 Reverse transcriptase PCR was used to generate an HA-tagged PfPK5 with flanking 
AvrII and Xho1 cut sites from a P. falciaprum mRNA library. PfPK5 is 867bp.  The HA tag and 




the unpurified PCR product with a strong band at approximately 900bp.  The recombinant 
PfPK5-HA gene was ligated into a pGEMT Easy vector (3015bp) and transformed into E.coli 
XL10 Ultra-competent cells.  Ligation colonies were miniprepped and screened by digestion 
with Xho1 and AvrII.  The digested DNA was run on an agarose gel revealing bands at 
approximately 900bp and 3000bp as seen in figure 11.  The clones were also confirmed by 
dideoxy sequencing.   
 To facilitate ligation of PfPK5-HA into a pDC2-1600-GFP-MAHRP (8349bp) construct 
for malarial transfection the construct was digested with AvrII and Xho1 which removed the 
GFP-MAHRP cassette.  The digest was run on an agarose gel (fig 12B) and the pDC2-1600 
(6822bp) vector backbone extracted.  The PfPK5-HA-pGEMT was also digested with AvrII and 
Xho1, run on an agarose gel (fig 12A) and the PfPK5-HA insert was extracted.  The gel extracts 
were purified and ligated with quick ligase.  Colonies were cloned into E. coli XL10-gold ultra-
competent cells and screened via an Xho1 and AvrII double digest.  Screening results can be 
seen in figure 13. Two clones show bands at 900bp and 7000bp.  These bands were sequence 
confirmed. 
 







Figure 10 - Agarose gel of PfPK5-
HA PCR.  Product shows a band at 
900bp.   
Figure 11 - Screening of PfPK5-
HA-pGEMT clone by digestion 
with AvrII and Xho1 shows 
bands at 3000bp and 900bp on 











Figure 14 - Screening of PfPK5-HA-pDC2-1600 clones by digestion with AvrII and Xho1 shows that clones 2 and 3 









Figure 12 - Agarose gel of double 
digest of PfPK5-HA-pGEMT with 
AvrII and Xho1 yields PfPK-HA at 
900bp and 3000bp 
Figure 13 - Agarose gel of double digest of 
PfPK5-HA-pGEMT with AvrII and Xho1 





PfPK5-HA Transfection Shows Expression of the HA 
The transfection efficiency of P. falciparum is extremely low.  Episomal transfections are 
difficult to propagate through the entire life cycle because they can be lost during mitotic 
segregation (15).  In order to overcome this deficiency, a transfection method mediated by 
Mycobacterium Bxb1 integrase was developed. This integration method will facilitate 
homologous crossover of the gene with a specific site on the parasitic chromosome.  The 
crossover event occurs between an attP site on the vector and an attB site on the chromosome 
and is performed by mycobacteriophage Bxb1 integrase.  P. falciparum cell lines were generated 
with the attB crossover sites (15).  The attB vector that carries the gene of interest contains a 
blasticidin (BSD) marker for selection.  The vector that expresses the integrase enzyme (pINT 
vector) has a neomycin marker and is transiently co-transfected with the integrase construct.  The 
co-transfection allows for larger gene sequences to be inserted into the integrase vector and 
allows for more efficient recombination (15).  Once the chromosomal crossover has occurred the 
parasite will no longer need antibiotic treatment as the unneeded vector will be lost. 
Following the transfection of synchronized malarial culture western blotting was used to 
determine if PfPK5-HA was being expressed.  Western blotting against PfPK5 shows that PfPK5 
(33kDa) has higher expression in the transfected culture as opposed to the untransfected malarial 
culture (fig 14).  Western blotting against the HA tag shows that HA is only present in the 





Figure 15 - Anti-PfPK5 western blot shows that PfPK5 (red arrow at 33kDa) is more highly expressed in the PfPK5-





Figure 16 - Anti-HA western blot shows HA tag expression at ~33kDa (red arrow) only in the PfPK-HA transfected 
culture (PfPK5). 3D7: untransfected P. falciparum culture 
PCR Screening Demonstrates PfPK5-HA Was Not Integrated into the Parasite CG6 Locus 
 A genomic DNA extraction was used to isolate nuclear DNA from the PfPK5-HA 
transfected line to screen for integration via PCR.  PfPK5-HA-pDC2-1600 integration would 
disrupt the CG6 gene of P. falciparum 3D7, a nonessential gene.  Three PCR reactions were set 
up.  One reaction used a forward primer that recognizes the parasite chromosome (5’ end of the 
CG6 gene) and a reverse primer that recognizes the construct (3’ end of the BSD gene used as a 
selective marker).  Another reaction uses a forward primer that recognizes the construct (5’ end 
of the PfPK5 gene) and a reverse primer that recognizes the parasite (3’ end of the CG6 gene).  
The last reaction was set up using the 5’ and 3’ end of the CG6 gene (chromosomal recognition).  




reactions that used primers against the construct and the parasite chromosome show no bands 
while the reaction that used chromosomal primers show a small band around 300bp.  
 
PfPK5-HA Does Not Co-localize with Endogenous PfPK5 
 IFAs against endogenous PfPK5 and PfPK5-HA were performed to determine if the 
expressed PfPK5-HA was localizing with endogenous PfPK5.  Figure 17 demonstrates that 









M 1 2 3 Figure 17 Agarose results from 
screening of PfPK5-HA-pDC2-
1600 chromosomal integration 
by PCR. 
Lane 1: Primers 1 and 2 
Lane 2: Primers 3 and 4 
Lane 3: Primers 1 and 4 
 
Primer 1: 5’ of CG6 gene (gene 
interrupted) 
Primer 2: 3’ of BSD gene 
Primer 3: 5’ of PfPK5 gene 
Primer 4: 3’ of CG6 gene 
Figure 18 - PfPK5-HA vs PfPK5 IFA results show that recombinant PfPK5 (green) did not co-localize with 
endogenous PfPK5 (red).  The nucleus is stained blue with DAPI.  PfPK5-HA localization is shown in green 





 PfPK5 demonstrates predominantly nuclear localization (fig 2).  This data reinforces 
PfPK5’s suggested role in nuclear processes.  PfPK5 also showed co-localization with PfCyclins 
(fig 3-5).  The tightest co-localization was observed between PfCyc3 and PfPK5 suggesting that 
PfCyc3 may interact with PfPK5.  The expression profile of PfPK5 (fig 6- and 8A) demonstrates 
cyclical expression throughout the intra-erythrocytic life cycle of P. falciparum increasing from 
early infection to late infection.  PfPK5 expression peaks during the late schizont stage which is 
the stage responsible for mitotic events, indicating that PfPK5 may be involved in this nuclear 
process.  PfCyclin3 demonstrates the same cyclical expression pattern also showing peak 
expression levels during the schizont stage (fig 7 and 8B).  Based on their corresponding 
expression patterns there may be a correlation between the up-regulation of PfCyc3 and PfPK5 
during the schizont stage.  This is seen in most CDK/cyclin relationships in which oscillating 
levels of cyclins activate steady-state levels of the CDK.  Thus, co-localization and expression 
studies suggest that PfCyc3 may be involved in the regulation of the PfPK5 signaling pathway 
and that the PfPK5 signaling pathway may be involved in Plasmodium’s divergent mitotic 
processes.   These results support our previous published work which shows that the RNA 
polymerase C-terminal domain phosphorylation by PfPK5 was significantly stimulated by 
recombinant PfCyc3 (Merckx et al, 2003, JBC). 
 PfCyc3 was visualized at 52kDa after migration through an SDS gel.  Interestingly 




ubiquitination.  Cyclins are synthesized and degraded in a cyclical pattern that aids in the 
progression of the cell cycle, thus cyclins are commonly ubiquitinated.  
 The anti-PfPK5 immunoprecipitation revealed 4 bands in the PfPK5 elution upon 
analysis by SDS-PAGE and silver staining.  Red arrows in figure 8 at 150kDa, 100kDa, 70kDa 
and ~30kDa represent potential PfPK5 interactors.  Mass spectrometry will be used to identify 
these proteins.  The potential of these proteins to serve as PfPK5 regulators or substrates will be 
deduced via bioinformatic analysis.  Further localization and expression studies will determine if 
the indicated proteins are physically able to interact with PfPK5.  In vitro kinase assays will 
validate if the putative interacting partners are substrates of PfPK5.  Proteins that demonstrate 
interaction but do not show phosphorylation by PfPK5 may be regulators of the PfPK5 pathway.  
There are also distinct bands at ~50kDa and ~25kDa.  These are the relative sizes of the heavy 
and light chains of antibodies and these bands may therefore be attributed to PfPK5 antibody that 
came loose from the resin when the beads were boiled (see methods).  Determination of PfPK5 
interacting partners will aid in illumination of the pathways responsible for Plasmodium’s 
untraditional cell cycle.  Plasmodium proteins that associate with a crucial cell cycle regulator 
such as PfPK5 may prove to be novel drug targets.  Further characterization of PfPK5’s 
interacting partners will also provide more insight into the structure PfPK5 assumes when 
binding to these proteins and therefore help guide rational drug design. 
 The recombinant PfPK5 gene is about 906bp.  The PCR product in figure 10 resulted in a 
band around 900bp indicating successful generation of the HA-tagged PfPK5.  After ligation into 




yields bands around 3000bp and 900bp.  The pGEMT Easy vector is 3015bp and PfPK5-HA is 
916bp so bands at 3000 and 900 indicate a successful ligation which was confirmed by DNA 
sequencing.  Digestion of the PfPK5-HA-pGEMT construct was performed again to extract the 
PfPK5-HA insert for ligation into the pDC2-1600 vector (fig 12A).  The vector was prepared by 
digesting pDC2-1600-GFP-MAHRP with Xho1 and AvrII as well (fig 12B).  The GFP-MAHRP 
cassette was left behind and the vector backbone extracted (~6822bp).  Purified vector and insert 
extracts were ligated and clones screened again with Xho1 and AvrII (fig 13).  Lanes 3 and 4 
show bands around 900bp and 7000bp that indicate the PfPK5-HA gene and the pDC2-1600 
vector respectively.  The other lanes represent clones that did not take up a successfully ligated 
construct.  The construct was used for transfection after sequence confirmation by dideoxy 
sequencing. 
 Western blotting showed expression of the HA-tag in the transfected line only (fig 15). 
The HA tag is on the C-terminus of PfPK5 therefore expression of HA would require expression 
of PfPK5. It was also shown that PfPK5 was more highly expressed in the transfected line (fig 
14) as would be expected with the introduction of a duplicate PfPK5 gene. Both the HA and 
PfPK5 bands are visualized at ~33kDa indicating that the H-tag was not cleaved from PfPK5 
post-translationally or otherwise altered after expression. Western blotting thus confirms 
expression of PfPK5-HA. 
 However, PCR results show that while expressed, PfPK5-HA was not integrated into the 
parasite’s endogenous CG6 gene (fig 16). In the first PCR reaction (fig 16 lane 1) a forward 




construct (3’ of BSD gene) were utilized.  The absence of a band indicates that primers were not 
able to bind the same strand of DNA, an indication that integration at the CG6 site did not occur.  
The second PCR reaction (lane2) also used a primer recognizing the chromosome (3’ of CG6) 
and one recognizing the construct (5’of PfPK5).  Again elongation and amplification were not 
observed.  The final PCR reaction (lane 3) contained the 3’ and 5’ end of the CG6 gene, which 
would be disrupted upon integration of the construct.  This PCR reaction resulted in a small band 
around 300bp, indicative of amplification of the CG6 gene.  Had the construct been integrated a 
much larger PCR product would have been visualized as the entire construct (~8kb) is integrated 
into the CG6 loci of the chromosome.  In addition to the absence of PCR products, IFAs also 
show that PfPK5-HA does not co-localize with endogenous PfPK5 (fig 17).  Since the 
recombinant PfPK5 was expressed it can be suggested that the transfection was not integrated, an 
episomal transfection occured, or that it was integrated at a different site on the chromosome.  Its 
localization to a subcellular compartment other than the nucleus suggests that if the gene was 
integrated part of the gene sequence was altered or lost.  As a result the recombinant PfPK5 did 
not localize with its endogenous substrates and would therefore be unable to interact with them.  
A southern blot was also performed to confirm PCR results and determine if the recombinant 
PfPK5 was integrated elsewhere in the chromosome.  This data has yet to be analyzed (being 
developed).  
Significance of Work 
 The information gained from this experiment shows PfPK5 is nuclear and it can be 




division.  Peak expression of PfPK5 during the late schizont stage hints at the later.  PfCyc3 and 
PfPK5 coordinated expression levels and co-localization strongly suggests that they are 
interacting partners.  Also several potential interacting partners have been isolated and upon 
identification and further characterization these proteins may prove useful in the illumination of 
Plasmodium’s enigmatic cell cycle events.   
 Although the first transfection did not show integration of the PfPK5-HA into the correct 
locus, generation of this recombinant gene will serve to confirm data gathered here and reduce 
false positives in future studies. 
  Knowledge gained here may aid in rational drug design.  PfPK5 substrates or regulators 
may be specific to Plasmodium, an ideal characteristic of a potential drug target.  Also, with the 
structure of PfPK5 determined and the Plasmodium genome completed, unmasking PfPK5 
interacting partners will facilitate characterization of the interface between the interacting 
proteins.  Targeting the substrate-PfPK5 interface would increase selectivity of putative drugs, a 
challenging aspect in the design of kinase-targeted drugs; a result of highly conserved kinase 
domains.  In addition to identifying the PfPK5 signaling pathway as a potential drug target, 
further elucidation of the regulatory mechanisms responsible for Plasmodium’s atypical cell 
cycle phases will promote knowledge of the organism’s ability to thrive in human red blood 
cells.  Ultimately a better understanding of these processes will lead to the generation of new 
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